Shigella species are rarely associated with extraintestinal disease. We recently treated a patient with vertebral osteomyelitis due to Shigella boydii. In a comprehensive search of the Englishlanguage literature for the period 1970 to 1994 (with the use of MEDLINE and a review of secondary references), we found only three published reports of human bone and/or joint infection due to Shigella species [1][2][3]. We report, to our knowledge, the first case of vertebral osteomyelitis due to Shigella species.
Vertebral Osteomyelitis Due to Shigella boydii
Shigella species are rarely associated with extraintestinal disease. We recently treated a patient with vertebral osteomyelitis due to Shigella boydii. In a comprehensive search of the Englishlanguage literature for the period 1970 to 1994 (with the use of MEDLINE and a review of secondary references), we found only three published reports of human bone and/or joint infection due to Shigella species [1] [2] [3] . We report, to our knowledge, the first case of vertebral osteomyelitis due to Shigella species.
A 69-year-old man presented to our hospital, for the first time, with back pain and weakness and sensory loss in the lower extremities. He had been in good health until 2 1/ 2 months before admission, when he had developed back pain and leg numbness. Two weeks later, an MRI study performed elsewhere demonstrated an infection of the ninth thoracic disk space with associated epidural abscess; he underwent decompressive laminectomy. Pathological studies revealed acute inflammation; cultures were reported as yielding "diphtheroids." A CT-guided biopsy of the same area was performed 3 days later to better define the etiology of the infection, but cultures were negative for bacteria. He was treated with iv cefazolin for 6 days, followed by oral cephalexin for 5 weeks. While he was receiving antibiotics, his back pain gradually abated, and he progressed from using a wheelchair to using a walker, and finally to walking with a cane. However, the numbness in his lower extremities persisted.
Shortly after treatment with cephalexin was discontinued, the patient developed increasing back discomfort and increasing numbness and decreasing strength in the lower extremities. Approximately 3 days before admission to our hospital, he developed constipation, obstipation, and urinary retention. He was admitted to our neurological intensive care unit.
The patient resided in Minnesota. He was a hunter and had traveled to Mexico for vacations every year; his last trip had been 10 months before his admission to our institution. He had glaucoma but was in otherwise good health. He reported no systemic or local symptoms. Specifically, there was no history of diarrheal or gastrointestinal illness.
On physical examination, he was afebrile and had mild weakness and hyporefiexia of the lower extremities and sensory loss below the tenth thoracic level. His WBC count was 10.9 X 10 9 , and his erythrocyte sedimentation rate was 85 mm/h. Cultures of blood and urine were negative.
An MRi study demonstrated osteomyelitis of the ninth and tenth thoracic vertebral bodies, diskitis of the ninth thoracic interspace, and an epidural abscess extending from the fifth to the eleventh thoracic vertebral bodies (this had progressed since MRI had been performed 2 months earlier). A myelogram demonstrated compression of the spinal cord at the level of the ninth and tenth thoracic vertebral bodies.
The patient underwent a revision posterior decompressive laminectomy of the eighth through eleventh thoracic vertebrae, with a transpedicular biopsy of the tenth thoracic vertebral body. Anterior decompression and debridement were not performed because of the need for transection of the segmental vascular supply to the spinal cord and the associated risk of further vascular insult. Purulent material was found in the epidural space and in the tenth thoracic vertebral body; pathological studies of specimens from these two areas demonstrated acute inflammatory cells and osteomyelitis, respectively. Cultures of specimens taken from the disk space, epidural space, and vertebral body yielded a gram-negative bacillus, which was identified by the Minnesota State Department of Health as S. boydii. The organism was susceptible to cefazolin, amikacin, gentamicin, mezlocillin, trimcthoprim-sulfamethoxazole, imipenem, and ciprofloxacin, and it was resistant to ampicillin and chloramphenicol. Stool cultures were negative, but they were performed after the patient had received antimicrobial treatment.
He was braced in a thoracolumbar sacral orthosis and treated with cefazolin for 6 weeks. He continued to have mild weakness of the left leg postoperatively, with numbness of both lower extremities, and urinary retention; he remained hospitalized for 3 1/ 2 weeks while undergoing physical rehabilitation. At follow-up 5 months after admission to our institution, sensory and motor function of his lower extremities had improved.
Our patient represents the first reported case of vertebral osteomyelitis due to Shigella species. His only obvious exposure to the organism was his trip to Mexico; however, this trip had preceded his presentation by several months. The reason for the negative cultures (with the exception of "diphtheroids") of material obtained during his prior laminectomy is enigmatic; the possibility that this infection was acquired intraoperatively seems unlikely but cannot be excluded. The reason for his failure to respond to the initial treatment likely consists of a combination of inadequate length of effective intravenous antimicrobial therapy and inadequate debridement. We report, to our knowledge, the first case in which cefazolin was used to treat extraintestinal shigella infection. Theinhibitory activityof acycloviris basedon itsphosphorylation by the viralthymidine kinase(TK). Afterpatientswith AIDSreceive long-termtreatmentwith acyclovirfor the controlof infections with herpes zoster and herpes simplex viruses, resistant isolates may appear. Most of the resistant strains are either deficient in TK or inducea TK withan alteredsubstratespecificity [I, 2] . Foscarnethas a differentinhibitionmechanismand is the established alternative in these cases [3] . However, its toxicity and the need for intravenous administration are drawbacks. Sorivudine is one of the most active compounds against varicella-zoster virus (VZV) [4] and has favorable pharmacokinetics permitting once-daily administration. However, as its inhibitory mechanism is also based on the phosphorylation by the viral enzyme,strainswith an alteredTK [I, 5] may have reduced susceptibility to sorivudine as well.
Disseminated necrotic skin lesions developed in May 1994 in a 38-year-old woman with AIDS. These lesions diminished but never disappeared completely, despite the administration of high doses of oral acyclovir (5 X 800 mg/d), On 21 October outer retinal necrosis occurred in herrighteye.Treatment withfoscarnet (10g/d)was started on 23 October. The skin lesions healedbut she lostvision in her right eye, and the retinawas completely detached by 26 October.
On 7 November treatment with foscamet was interrupted because of renal failure, and treatment with sorivudine was started at reduced dosages of 40 mg every 2 days (usual dose, 40 rng/d). Skin lesions did not recur during therapy with sorivudine. However, retinal lesions appeared in her left eye on 8 December.Treatment with foscamet was started again, combined with intravitreal administration of ganciclovir (200 f-Lg twice weekly). The retinal lesions responded, but her vision decreased on 24 January 1995 and progressed to blindness on 27 January. Treatment with sorivudine was discontinued on II January because of thrombocytopenia (nadir 10,000 platelets/ul.), and foscamet was withdrawn on 8 February. The patient died on 15 March.
Before treatment with foscarnet was started, VZV was isolated from CSF obtained by a lumbar puncture (21 October 1994); the virus was grown on fibroblasts. No other viruses were detected at NOTE. Human foreskin fibroblasts were seeded in 12-well plates. VZVinfected cells were seeded at a concentration that yielded 50-100 plaques per well and were incubated in the presence of antiviral drugs. After 4 days of incubation, plates were fixed and stained with Wright-Giemsa.
*
that time in bronchoalveolarlavage fluid, blood, saliva, throat swab specimens, or urine. In addition,nested PCR revealedVZV DNA in anterior chamber fluid. PCR for cytomegalovirus, herpes simplex virus, and Toxoplasma gondii was negative. In each reaction with material from the patient, two H 20 samples were included as a negative control; a positive control was includedas well. Primers from the following genomic regions were used: the membrane glycoprotein gpIl region for VZV; the IE region for cytomegalovirus, the gene region of UL42 for herpes simplex virus, and the B, gene repeat for T. gondii. In addition, 10 f-LL of the extracted DNA was used to amplify the TNF-a gene in a single-round peR. The product of the inner PCR was checked for size on an agarose gel.
The VZV isolate replicated rapidly in cell culture, and the plaque reduction assay revealed resistance against acyclovir, ganciclovir, and BV-ARA-U (defined in table 1), although the patient had never been treated withBV-ARA-U before. The viruswassusceptible to foscarnet.
Long-term administration of acyclovir to this patient with AIDS selected multiresistant VZV, which was also resistant to the potent VZV inhibitor sorivudine. This multiresistance was probably due to an altered or lacking TK and left only foscamet as a treatment option, although this approach was seriously hampered by renaltoxicity. This observation demonstrates the need for alternative nontoxic antiviral drugs with different mechanisms than the inhibition of TK.
